Zafgen, Inc. (ZFGN)
| Market Cap | 3.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 37.47M |
| EPS (ttm) | -0.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 28, 2020 |
| Last Price | $0.990 |
| Previous Close | $0.990 |
| Change ($) | 0.000 |
| Change (%) | 0.00% |
| Day's Open | 1.020 |
| Day's Range | 10.000 - 12.510 |
| Day's Volume | 4,323,149 |
| 52-Week Range | 0.619 - 12.510 |
News
- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology...
Clinical-stage biopharma companies often face the risk of running out of cash reserves to fund their operations until they can push their investigational assets out of the clinics into the com...
Preliminary results from in vivo animal study not expected to warrant near-term resolution of clinical hold for ZGN-1061 Preliminary results from in vivo animal study not expected to warrant n...
Shares of Zafgen Inc (NASDAQ: ZFGN) were tumbling below the psychological barrier of $2 in Thursday's session.
Zafgem said it has planned to suspend to file an investigational new drug application, or IND, for its ZGN-1258, which it's evaluating for rare metabolic disorders including Prader-Willi syndr...
About ZFGN
Zafgen is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. (source: Wikipedia)
| Industry Biotechnology | IPO Date Jun 19, 2014 |
| CEO Jeffrey S. Hatfield | Employees 7 |
| Stock Exchange NASDAQ | Ticker Symbol ZFGN |